MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

3.06 5.52

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.82

Max

3.15

Põhinäitajad
By Trading Economics
Sissetulek	-31M -14M
Müük	-32M 41M
Aktsiakasum	-0.22
Kasumimarginaal	-34.333
Töötajad	293
EBITDA	-37M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+37.93% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	53M 175M
Eelmine avamishind	-2.46
Eelmine sulgemishind	3.06

Uudiste sentiment

By Acuity

50%

166 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2026, 17:11 UTC

Suurimad hinnamuutused turgudel

Uudisväärsed sündmused

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2. apr 2026, 17:10 UTC

Uudisväärsed sündmused

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3. apr 2026, 00:00 UTC

Uudisväärsed sündmused

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2. apr 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Capital Finalize China JV

2. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. apr 2026, 20:41 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2. apr 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2. apr 2026, 20:01 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2. apr 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2. apr 2026, 19:29 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:24 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2. apr 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2. apr 2026, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2. apr 2026, 19:00 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Agreement Reached With American Train Dispatchers Association

2. apr 2026, 18:24 UTC

Omandamised, ülevõtmised, äriostud

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2. apr 2026, 17:44 UTC

Market Talk

Uudisväärsed sündmused

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2. apr 2026, 17:32 UTC

Uudisväärsed sündmused

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2. apr 2026, 17:26 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2. apr 2026, 17:09 UTC

Market Talk

Uudisväärsed sündmused

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

37.93% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 37.93%

Kõrge 4 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

166 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.